Raymond James analyst Ryan Deschner initiates coverage on ADMA Biologics (NASDAQ: ADMA) with a Outperform rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage